Navigation Links
Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care

oellex, the Company's lead compound, a PRM (progesterone receptor modulator) has recently completed a successful U.S. three-month Phase 2 clinical trial for the treatment of uterine fibroids, a condition that affects numerous women of childbearing age in the United States and results in a significant number of hysterectomies each year. Proellex has recently completed a six-month European Phase 1/2 study for the treatment of endometriosis, a condition that affects approximately 5.5 million women in the United States and Canada. Androxal(TM), the Company's other program in late clinical development, is designed to restore normal testosterone production by the testes in men and has recently completed a six-month U.S. non-pivotal Phase 3 clinical trial for the treatment of testosterone deficiency due to secondary hypogonadism. According to industry sources, approximately 13 million men in the United States experience testosterone deficiency. The Company is planning meetings with the FDA for all three programs to lay out the remaining clinical program pathway required before a New Drug Application may be submitted for each product candidate.

For more information, please visit the Company's website at http://www.reprosrx.com.

Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Repros' ability to have success in the clinical development of its technologies, the timing of enrollment in such clinical studies and the accuracy of such studies, Repros' ability to raise additional capital on acceptable terms or at all, and such other risks which are identified in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, and Repros' Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, as they may be updated by the Company's Exchange Act filings from time to time. These documents are available on request from Repros Therapeutics or at
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
3. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:7/1/2015)... Ariz. , July 1, 2015 Prismic ... drugs and FDA-regulated medical foods, today announced the election ... A. Simonetti to its Board of Directors. ... Board members, Peter Moriarty , Chairman and CEO ... Krivulka and Martin Simonetti have accepted ...
(Date:7/1/2015)...  Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ), ... commercialization of proprietary compounded drug formulations, today announced ... market closing bell on Thursday, July 2, 2015.  ... Go Dropless™ campaign since its launch in April ... annually in the U.S. and more than 4.3 ...
(Date:7/1/2015)... ExeGi Pharma, a company focused on developing ... that it has been granted a product license by ... (NNHPD) to sell Visbiome™ in Canada ... Claudio De Simone , MD, PhD and has ... Simone recently signed an exclusive agreement with ExeGi Pharma ...
Breaking Medicine Technology:Joseph Krivulka and Martin Simonetti Join Board of Prismic Pharmaceuticals 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3
... Jan. 19, 2011 On February 1, 2011, the ... Center for Biomedical Innovation, and Engineering Systems Division will ... Systems Thinking from Discovery to Delivery ... day-long event, sponsored by Merrimack Pharmaceuticals, will be a ...
... RFID Journal features MEPS Real Time,s ... live or die depending on the correct medications being ... tracking of a drug,s expiration dates, information about the ... in REAL TIME, would assist in preventing errors. ...
Cached Medicine Technology:Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 2Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 3Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 4Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 5Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 6Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 7Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 8MEPS Real Time's New RFID Drug Management System Provides Critical Error Solution for California Hospital 2
(Date:7/2/2015)... ... July 02, 2015 , ... ... products, services, channels and business models. To help manage the increasing demand for ... of Mark Benkendorf as SVP of Strategic Engagements. , Benkendorf is a seasoned ...
(Date:7/1/2015)... ... July 01, 2015 , ... With ... St. Joseph’s Health, located in Syracuse, N.Y., is now a member of national ... gained an admirable and important partner committed to delivering high-value care, said Richard ...
(Date:7/1/2015)... ... July 01, 2015 , ... The federal ... ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion for Summary Judgment. According to ... on June 26th, the Court rejected the Plaintiff’s assertion that one manufacturer ...
(Date:7/1/2015)... ... 01, 2015 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... to their industry leading Scientific Advisory Board. LRF’s volunteer Scientific Advisory Board (SAB), ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... forms, such as organically raised chickens and eggs. Eating organic foods and products ... is cleaner and more environmentally friendly than production chicken farming. Choosing home raised ...
Breaking Medicine News(10 mins):Health News:Business Builder Mark Benkendorf Joins Innovation Firm Maddock Douglas 2Health News:St. Joseph’s Health Now a Member of Trinity Health 2Health News:St. Joseph’s Health Now a Member of Trinity Health 3Health News:St. Joseph’s Health Now a Member of Trinity Health 4Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2
... (HealthDay News) -- Patients with do-not-resuscitate (DNR) orders are more ... non-emergency procedures, a new study finds. DNR orders request ... who is clinically unresponsive and lacks a pulse. ... print issue of the journal Archives of Surgery . ...
... Infection with mononucleosis -- the easily spread virus that,s the ... sunlight may combine to boost a person,s risk for developing ... common at higher latitudes, farther away from the equator," the ... of Oxford in England, said in a statement provided by ...
... sleep medicine professionals from around the world will gather ... of Dental Sleep Medicine (AADSM), which will take place ... Minneapolis, Minn. The meeting will be held in conjunction ... Associated Professional Sleep Societies. The AADSM 20th ...
... OTTAWA, ONTARIO, CANADA Canada needs to modernize its ... well as older drugs are safe for Canadians, states ... Association Journal ) http://www.cmaj.ca/cgi/doi/10.1503/cmaj.110489 . "Canadians are ... Act that,s a dusty relic, virtually untouched since 1953," ...
... Prozac: new drug offers hope for depression ... from depression, and though the symptoms might be ... incompletely understood. Research suggests that aberrant signaling by ... its receptor TrkB, may contribute to anxiety and ...
... one in 10 American babies are born prematurely, there have been ... arrive too early until now. A new study suggests ... in advance with a blood test taken during the second trimester ... assessing risk," said Steven Graves, who directs the chemistry portion of ...
Cached Medicine News:Health News:People With DNR Orders More Apt to Die After Any Surgery 2Health News:Can Common Virus, Lack of Sunlight Boost MS Risk? 2Health News:JCI online early table of contents: April 18, 2011 2Health News:JCI online early table of contents: April 18, 2011 3Health News:JCI online early table of contents: April 18, 2011 4Health News:JCI online early table of contents: April 18, 2011 5Health News:JCI online early table of contents: April 18, 2011 6Health News:JCI online early table of contents: April 18, 2011 7Health News:Predicting premature birth possible through markers in mother's blood 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: